Embed Size (px)
Citation preview
1 | P a g e
Press release – For immediate release
February 27, 2018 – 5:45pm CET
Median Technologies and CMIC HOLDINGS Co., Ltd. announce agreement to provide comprehensive clinical trial services
Collaboration will enable best‐in‐class services for oncology clinical trials in Japan, China and East Asia
Sophia Antipolis, France and Tokyo, Japan – February 27, 2018 ‐ Median Technologies, the industry‐
leading Imaging Phenomics Company® (Paris: ALMDT) and CMIC HOLDINGS Co., Ltd. (CMIC), a
leading Contract Research Organization (CRO) with services for development, manufacturing, sales,
and marketing of pharmaceutical products, today announced a collaborative agreement for
comprehensive clinical trial services. Together, Median and CMIC will leverage complementary
expertise to help biopharmaceutical companies accelerate oncology drug development in Japan,
China and East Asia.
The agreement came following an onsite audit at Median’s headquarters in France late last year.
Through the collaboration, CMIC will access Median’s innovative imaging technologies, services and
imaging expertise. It also extends Median’s access to biopharmaceutical sponsors with clinical trials
in Asia. Median and CMIC will promote and deliver their combined services to speed oncology drug
development and provide innovative therapies to patients who need them.
“The agreement with CMIC, a leading CRO in Asia, is a landmark event for Median Technologies.
With our enhanced technology and in‐depth expertise in oncology medical image interpretation and
management, we complement their offering in a key area of growth.” said Nicholas Campbell, Chief
Commercial Officer at Median Technologies. “We have been accelerating our expansion in Asia with
the opening of our subsidiary in Shanghai and recent key new hires in Japan and China. Our CMIC
collaboration strengthens our efforts and extends our footprint for our clinical trial business in the
fast‐growing Asian market. We look forward to a fruitful partnership,” added Campbell.
“The collaboration with Median will further strengthen CMIC's oncology trial capabilities. This
partnership with Median will reinforce CMICs One‐Stop‐Service advantage by allowing our
biopharmaceutical clients to access Median's innovative imaging technologies and expertise in
addition to CMIC’s strong experience in oncology trials. We believe this will allow us to provide more
satisfying services to our clients. Through this cooperation, we would like to continue building more
partnerships in oncology between our two companies,” said Toru Fujieda, Managing Director,
Executive Corporate Officer of CMIC HOLDINGS.
About CMIC HOLDINGS Co., Ltd.: CMIC Group started business in 1992 as the first CRO in Japan, and the
company today provides comprehensive support services for development, manufacturing, sales, and
marketing of pharmaceutical products. Also, the company operates to respond to diversifying needs by
managing the Healthcare Business sector and developing and selling diagnostic pharmaceuticals and orphan
2 | P a g e
drugs. CMIC Group has developed a unique business model that we call “Pharmaceutical Value Creator (PVC)”
based on our abundant accumulated experience and knowledge as a CRO pioneer. CMIC utilize PVC to create
new value in the healthcare field. For more information, visit our website: www.cmicgroup.com/e
CMIC HOLDINGS Co., Ltd. Contact:
Corporate Communication Division PR Group
Tel: +81‐3‐6779‐8200
E‐mail: [email protected]
About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions, MediScan® for Patient Care, iSee® for image management in clinical trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports
biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia‐Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA‐PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2017‐2018. Median Technologies has been awarded the 2017 Tech 40 Label, has joined the EnterNext Tech 40 Index and is a winner of the Deloitte Technology Fast 500™ 2017 EMEA program. Median is a member of the Bpifrance Excellence Network. For more information: www.mediantechnologies.com
Contacts
Median Technologies Marjorie Kooman
VP, Head of Investor and Media Relations
+1 312 282 3923 [email protected]
Press ‐ ALIZE RPCaroline Carmagnol/Wendy Rigal + 33 1 44 54 36 66 [email protected]
Investors ‐ ACTIFINGhislaine Gasparetto +33 1 56 88 11 11 [email protected]
